Business Wire

Synchronoss Technologies Signs Agreement to Acquire honeybee

Share

Synchronoss Technologies, Inc. (NASDAQ:SNCR), a global leader and innovator of cloud, messaging, digital and IoT products and platforms, today announced it has signed an agreement to acquire Dixons Carphone plc’s honeybee software business, a leading provider of digital solutions targeted at optimizing the customer experience.

honeybee offers a proven, market-leading digital transformation platform that makes it easier for companies to design and launch exceptional omni-channel customer journeys. Customers of the honeybee platform, such as mobile operators and other communication service providers, can rapidly create and adapt digital sales processes for contact centres, retail stores, and online channels. This reduces complexity for the end-user as well as internal employees, while delivering a single customer experience at all touch-points and improved business outcomes such as reduced cost and increased revenue.

With this proposed acquisition Synchronoss will further strengthen its Digital solutions portfolio by adding enhanced platform capabilities and speed of execution to build, deploy and manage omni-channel customer journeys through retail stores, contact centres and online channels.

“honeybee’s digital platform will further augment our industry-leading expertise in optimizing digital channels to deliver an outstanding experience to the customers of Telecommunications, Media and Technology organizations,” said Glenn Lurie, President and CEO, Synchronoss. “Our acquisition of honeybee Solutions is a key component of our future product strategy to deliver true omni-channel solutions and is indicative of our aggressive investment in Digital. We’re committed to exceeding market expectations around cross-channel customer and employee experience, as this deal ultimately proves.”

The acquisition is expected to close towards the end of May.

About Synchronoss

Synchronoss (NASDAQ: SNCR) transforms the way companies create new revenue, reduce costs and delight their subscribers with cloud, messaging, digital and IoT products, supporting hundreds of millions of subscribers across the globe. Synchronoss’ secure, scalable and groundbreaking new technologies, trusted partnerships and talented people change the way Technology-Media-Telecommunications customers grow their business. For more information, visit us at www.synchronoss.com

Contact information

CCgroup
US:
Diane Rose, 727-238-7567
or
International:
Sarah Walker, +44 20 3824 9200
synchronoss@ccgrouppr.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Gain Therapeutics SA Announces Award Notification of a €1.4M Grant Support From Eurostars-2 Together With the Institute for Research in Biomedicine and Neuro-Sys SAS After Having Scored 2nd Among 325 Eligible Applications23.7.2019 06:30:00 CESTPress release

Gain Therapeutics SA, a biotechnology company discovering and developing novel therapeutics to target lysosomal enzymes involved in inborn errors of metabolism and in central nervous system (CNS) diseases, today announced that together with Dr. Maurizio Molinari from the Institute for Research in Biomedicine, Bellinzona (Switzerland) affiliated to the Università della Svizzera italiana (USI) and Neuro-Sys SAS in Gardanne (France), it has received funding support from Eurostars-2 joint programme with co-funding from the European Union Horizon 2020 research and Innosuisse – Swiss Innovation Agency. This grant will further strengthen Gain Therapeutics’s novel therapeutic approach for targeting rare diseases in the CNS, where lysosomal misfolded enzymes lead to sever clinical phenotypes, where no treatment is available and/or high unmet medical needs still do afflict patients, families and carers. This funding will support the development of the drugs portfolio of Gain Therapeutics for the

iBASIS Accelerates Growth With JC Geha as Chief Operating Officer23.7.2019 06:00:00 CESTPress release

iBASIS, provider of communications solutions for operators and digital players worldwide, today announced the appointment of JC Geha as its COO. He will take his new post effective August 1, and be based at iBASIS’ headquarters in Lexington, Massachusetts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190722005757/en/ JC Geha (Photo: Business Wire) Formerly Senior Vice President, Head of International Technology and Services for Deutsche Telekom, and of Managed Services for Ericsson, Geha brings to iBASIS an impressive track record of profitable growth, technology and digital transformation expertise. His expertise spans 25 years of deep global industry relationships across the United States, Europe, Middle East, and Africa. Geha will lead iBASIS’ global operations, engineering, IT, and product development. He will report to iBASIS’ CEO and founder of the Group Tofane Global, Alexandre Pébereau, with the responsibility of g

Abzena Announces Successful Technical Transfer of Synaffix GlycoConnect™ Antibody Drug Conjugate (ADC) Technology to Enable Use in Client Projects23.7.2019 06:00:00 CESTPress release

Abzena, the global partner research organization, announced it has successfully completed a technology transfer and scalability evaluation using the Synaffix technologies of GlycoConnect™ (antibody conjugation) and HydraSpace™ (highly polar spacer). Familiarity with these Antibody-Drug Conjugate (ADC) technologies adds to Abzena’s leadership in process development and GMP manufacturing of ADC linkers and payloads. Abzena can now rapidly ramp up ADC projects using Synaffix technology with high scientific quality. Jonathan Goldman, MD, Abzena CEO added: “Abzena believes in patient first drug development. Our expertise and experience with Synaffix GlycoConnect™ and HydraSpace™ technology further advances our leadership across multiple platforms in ADC. We look forward to supporting our customers as they leverage Synaffix technology to rapidly advance ADCs from IND stage into early clinical development.” About Abzena Abzena provides the most complete set of solutions in integrated discover

Aroma Bit to Develop Smartphone Embeddable Ultra-compact Silicon CMOS Based Smell Sensor That Has Dog Nose Equivalent Resolution in 1mm Squared Die Size23.7.2019 01:30:00 CESTPress release

Aroma Bit launched a new subsidiary to develop the next generation smell sensor based on silicon CMOS sensor substrate that are ultra-compact, high resolution and low cost. The technology is realized by applying Aroma Bit developed smell sensor receptor membrane technology to ultra-sensitive silicon CMOS based ion imaging sensor technology developed by professor Kazuaki Sawada at Toyohashi University of Technology and associated companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190722005004/en/ Picture of 1mm squared die of silicon CMOS based smell sensor, with dog nose equivalent ~1,200 sensor pixels (Photo: Business Wire) Aroma Bit: http://www.aromabit.com Realizing smartphone embeddable smell sensor with dog nose equivalent ultra-high resolution smell sensor on only 1 millimeter square silicon die size Aroma Bit has developed and are currently selling a compact smell sensor that employs QCM or Quartz Crystal Micro

Logitech Delivers a Strong Start to Fiscal Year 2020 with Robust Sales and Profit Growth23.7.2019 01:00:00 CESTPress release

Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced financial results for the first quarter of Fiscal Year 2020. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190722005781/en/ Logitech delivers a strong start to Fiscal Year 2020 with robust sales and profit growth. (Graphic: Business Wire) Q1 sales were $644 million, up 6 percent in US dollars and 9 percent in constant currency, compared to Q1 of the prior year. Q1 GAAP operating income grew 46 percent to $47 million, compared to $32 million in the same quarter a year ago. Q1 GAAP earnings per share (EPS) grew 17 percent to $0.27, compared to $0.23 in the same quarter a year ago. Q1 non-GAAP operating income grew 11 percent to $67 million, compared to $61 million in the same quarter a year ago. Q1 non-GAAP EPS grew 15 percent to $0.39, compared to $0.34 in the same quarter a year ago. Cash flow from operations was $37 million, compared to $12 million in the sa

Gilead Presents New Data on Biktarvy® for the Treatment of HIV in Women and in Virologically Suppressed Patients With Known Resistance22.7.2019 16:00:00 CESTPress release

Gilead Sciences, Inc. (NASDAQ: GILD) today presented findings from two Phase 3 trials – a trial demonstrating the effectiveness of switching to Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg tablets, B/F/TAF) in women, and a trial evaluating the potential for the single tablet regimen to be an effective treatment option in virologically suppressed patients with known resistance to nucleo(s)tide or non-nucleo(s)tide reverse transcriptase inhibitors (NRTIs or NNRTIs). The use of Biktarvy in patients with known drug resistance is investigational. These data were presented at the 10th International AIDS Society Conference on HIV Science (IAS 2019) being held in Mexico City. “These data presented at IAS provide new information about the treatment of HIV among women and patients with known drug resistance,” said Diana Brainard, MD, Senior Vice President, HIV and Emerging Viruses, Gilead Sciences. “The studies further demonstrate the potential for Biktarvy to be an